Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22452838 | 0.87 | CAPN1 (0.58) | KMT2AHCRTR1HCRTR2CAPN1P2RX7 | |
| SCHEMBL28681218 | 0.87 | CAPN1 (0.58) | KMT2AHCRTR1HCRTR2CAPN1P2RX7 | |
| SCHEMBL24434877 | 0.85 | CAPN1 (0.51) | KMT2AHCRTR1HCRTR2CAPN1P2RX7 | |
| SCHEMBL4573105 | 0.82 | HCRTR1 (0.56) | KMT2AHCRTR1HCRTR2CYP3A4MMP1 | |
| SCHEMBL4573101 | 0.82 | HCRTR1 (0.56) | KMT2AHCRTR1HCRTR2CYP3A4MMP1 | |
| SCHEMBL24434971 | 0.79 | ALDH1A1 (0.51) | KMT2AFKBP1A | |
| SCHEMBL24434796 | 0.79 | KMT2A (0.57) | KMT2AHCRTR1HCRTR2CAPN1P2RX7 | |
| SCHEMBL927807 | 0.79 | KMT2A (0.57) | KMT2AHCRTR1HCRTR2CAPN1P2RX7 | |
| SCHEMBL2583749 | 0.79 | KMT2A (0.57) | KMT2AHCRTR1HCRTR2CAPN1P2RX7 | |
| SCHEMBL14285587 | 0.78 | HCRTR1 (0.47) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3930849-B1 | THIAZOLE DERIVATIVES AS PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
| CN-113993587-A | Thiazole derivatives as protein secretion inhibitors | 科智生命科学公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | KMT2A 4802/4885HCRTR1 4007/4885HCRTR2 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.